Edgar Filing: IMMUNOGEN INC - Form 4

IMMUNOGEN I Form 4										
Form 4 November 12, 2014 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction Form 5 obligations May continue. See Instruction Form 5 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940									OMB APPROVAL OMB 3235-0287 Number: January 31, Expires: 2005 Estimated average burden hours per response 0.5	
1(b). (Print or Type Respo	onses)									
1. Name and Address of Reporting Person <u>*</u> Goldberg Mark Alan			2. Issuer Name and Ticker or Trading Symbol IMMUNOGEN INC [IMGN]				5. Relationship of Reporting Person(s) to Issuer			
(Last) (First) (Middle) 41 GRASMERE ROAD			3. Date of Earliest Transaction (Month/Day/Year) 11/11/2014			(Check all applicable) <u></u> Director <u></u> Officer (give title below) <u></u> 10% Owner <u></u> Other (specify below)				
	4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 						
NEEDHAM, MA	A 02494						Person	wore than one it	epotting	
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivative	e Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	ansaction Date nth/Day/Year)	2A. Deemo Execution any (Month/Da	Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or d of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02) required to respond unless the form displays a currently valid OMB control number.										

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and Expiration	7. Title and Amour
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Date	Underlying Securit
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)		

Edgar Filing: IMMUNOGEN INC - Form 4

Derivative Security			or Disposed of (D) (Instr. 3, 4, and 5)							
			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amc or Num of St
Deferred Share Unit	\$ 0 <u>(1)</u>	11/11/2014	A		3,000		02/01/2015(3)(2)	<u>(2)</u>	Common Stock (2)	3,0
Stock option (right to buy)	\$ 10.1	11/11/2014	A		10,000		02/01/2015 <u>(4)</u>	11/11/2024	Common Stock	10,

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Goldberg Mark Alan 41 GRASMERE ROAD NEEDHAM, MA 02494	Х							
Signatures								
/s/ Craig Barrowns, attorney in fact		11/12/2014						

Signature of Reporting Person **Explanation of Responses:

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Date

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into (1)Common Stock on a one-to-one basis.
- The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement (2)from the Board of Directors.
- The deferred share units vest ratably over a one year period in quarterly increments beginning on February 1, 2015, contingent upon the (3) individual remaining a director as of each vesting date.

Exercisable as to 2,500 shares commencing on February 1, 2015, 2,500 shares commencing on May 1, 2015, 2,500 shares commencing (4) on August 1, 2015 and 2,500 shares commencing on November 1, 2015, contingent upon the individual remaining a director as of each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.